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Overview  
▪ Clinical pearls for neuropathy 
▪ Anatomic patterns to look for 
▪ Differential diagnosis 
▪ Diagnostic testing 
▪ Symptomatic treatment 
Case 1 
▪ 55yo male with 6-12 months of painful 
numbness in feet.  Began in toes and now 
involves balls of feet.  Worse when resting 
or sleeping.  No weakness. No back pain. 
▪ Exam reveals stocking like sensory loss in 
both feet to pin. Normal power.  Normal 
arm and knee reflexes and absent ankle 
jerks. 
History and Clinical Exam 
Bilateral lower extremity pain/burning/numbness 
▪ 1.  What systems are involved? 
– Motor, sensory, autonomic 
▪ 2.  What is the temporal evolution? 
– Acute, sub acute, chronic, progressive, relapsing 
▪ 3.  What is the distribution of weakness? 
– Distal, proximal, symmetric, asymmetric 
▪ 4.  What is the nature of sensory involvement? 
– Painful, burning, tingling, numb, ataxic 
– Rocks in my socks 





History and Clinical Exam 
▪ 5.  Could this be a hereditary neuropathy?  
– Slow progression, high arches, foot deformities 
▪ 6.  Could this be something else? 
– Hips, knees, and vascular disease 
 
▪ A thorough general exam is key. 
 
 
Patterns of Neuropathic Disorders 
▪ Symmetric diffuse weakness + sensory 
▪ Symmetric distal weakness + sensory 
▪ Asymmetric distal weakness + sensory   
▪ Asymmetric distal weakness, no sensory 
▪ Symmetric sensory loss, no weakness 




Image(s) have been 
omitted 
 Pes Cavus (high arches) 
Image(s) have been 
omitted 
Diseases Associated with Peripheral Neuropathies 
▪ Diabetes mellitus 
▪ Chronic renal disease 
▪ Carcinoma, paraneoplastic  
▪ Plasma cell dyscrasias 
▪ Post Gastric bypass 
▪ Rheumatoid arthritis 
▪ Sjogren’s syndrome 
▪ Scleroderma 
▪ Systemic lupus erythematosus 
▪ Hypothyroidism 





 ▪ Chronic liver disease 
▪ Herpes zoster, HIV, Lyme 
▪ Diphtheria 
▪ Vitamin B12, folate deficiency 
▪ Malnutrition 
▪ Sarcoidosis 
▪ Lymphoma, myeloma 
▪ Gout 
▪ Polycythemia vera 
▪ COPD 
▪ Tropical spastic paraparasis 
▪ Drugs, toxins, heavy metals 
▪ MLD, Refsum’s disease 
 
 
Patterns of “Neuropathy” 
▪ 1.  Polyneuropathy – Idiopathic, hereditary, immune 
mediated, metabolic, infectious, toxin, malignancy related 
▪ 2.  Focal Neuropathies – Vascuilitic (mononeuropathy 
multiplex), carpal tunnel, ulnar neuropathy, Bells, peroneal 
neuropathy, HNPP 
▪ 3.  Motor Neuropathy / Neuronopathy - ALS, 
multifocal motor neuropathy 
Small Fiber Predominant 















Large Fiber Predominant 




















• Chemotx- cisplatin, 
nitrofurantoin, taxol 
• thalidomide 
▪ Idiopathic sensory 
▪ Diabetes Mellitus 
▪ Hereditary 

















▪ Vitamin B6 
 
Approach to Neuropathy 
Why EMG/NCS? 
Tests nerve function 
Document presence and location of Neuropathy 
Identify peripheral modalities involved - 
Sensory, Motor, Autonomic, Polyradiculopathy  
Identify the predominant pathophysiology 
Axonal vs. Demyelination 
Uniform vs. Multifocal with conduction block 
Conduction slowing - hereditary?, acquired 
Radiation Plexopathy 
Establish temporal profile and prognosis 
 
Diagnostic Approach to Neuropathy 
Which serum studies? 
▪ Primary 
• CBC, CMP, ESR 
• FBS, Hemoglobin A1C 
• SPEP, IFE 
• B12, MMA, folate 
▪ Secondary 
• TSH, ANA, RPR, RF, CPK, SS A/B, cryoglobulins, 
hepatitis, ANCA, Vit E, lyme, HIV, heavy metals, 
homocysteine, Anti-MAG, Anti-GM1, Genetic (CMT), 
paraneoplastic. 
 





▪ Tumor Infiltration 
▪ ?CIDP, leprosy 
When Skin Biopsy 
▪ Can be done when no answers 
forthcoming and neuropathy affects small 
fibers 
• In most cases all studies are previously normal 
• Small punch biopsy of skin on thigh and ankle 
• Does not change treatment plan 
Case 1 
Idiopathic Sensory Polyneuropathy 
▪ Represents approx 1/3 of neuropathy patients 
▪ Diagnosis of exclusion - axonal pathology 
▪ Distal symmetric pain, numbness and tingling 
without weakness  
▪ Absent ankle reflexes 
▪ Mean age 50-60 
▪ Temp>pin>position 
▪ Minimal distal weakness 
Idiopathic Sensory Polyneuropathy 
▪ 70% of patients reach a plateau 
▪ Vast majority remain stable or progress 
slowly 
▪ Generally a benign course with maintained 
strength and ambulation 
▪ Symptomatic treatment  
 
Diabetic Neuropathy 
▪ 45-60% of all diabetics develop neuropathy 
▪ May be presenting sign in up to 5% of 
patients 
▪ Most common cause of non-traumatic 
amputations 
▪ Distal sensory > motor polyneuropathy 
– small fibers affected initially - pain and temp 
– weakness and autonomic dysfunction as well 
Diabetic Neuropathy 
Variations 
▪ Acute diabetic axonal polyneuropathy 
• worsening diabetes and weight loss, change in tx 
▪ Diabetic Amyotrophy 
• severe thigh/back pain with weakness, atrophy 
• CIDP-like variant - some response to IVIG 
▪ Cranial neuropathies - 3 and 6 







Symptomatic Treatment for  
Painful Polyneuropathy 
▪ Ulcer prevention, foot care 
▪ Symptomatic Treatments  
• Snug, warm socks; braces, physical therapy 
• NSAID’s 
• FDA approved Rx 
• TCA’s, Anticonvulsants 
• Topical Creams 
• Narcotics 
 
Symptomatic Treatment for 
 Painful Polyneuropathy 
▪ Duloxetine (Cymbalta) 
 
▪ Pregabalin (Lyrica) 
 
▪ Gabapentin (Neurontin) 
 
▪ 60-120mg daily 
 
▪ 50-150mg three times 
daily 
▪ Start 300mg at HS, up 
to 900mg TID 
Symptomatic Treatment for   
Painful Polyneuropathy 
▪ Amitriptyline (Elavil), 
Nortriptyline (Pamelor) 
 
▪ Carbamazepine (Tegretol) 
 
▪ Phenytoin (Dilantin) 
 
▪ Lamotrigine (Lamictal), Mexiletine, 
Narcotics, Baclofen (Lioresal), 
Clonazepam (Klonopin), Tizanidine 
(Zanaflex), Tramadol (Ultram), 
Venlafaxine (Effexor) 
▪ Start 10-25mg HS, up to 
150mg 
 
▪ 200-400mg daily 
 
▪ 300-400mg at bedtime 
 
 
Other Symptom Treatments 
▪ Capsaicin Cream 
▪ Amitriptyline / Lidocaine cream 
▪ Lidocaine patch 
▪ Acupuncture 




▪ A 32 year old woman with 10 days of progressive weakness and numbness. 
▪ Developed 2 weeks after several days of diarrhea and fever. 
▪ Pins and needles in both feet and hands followed by progressive weakness 
of both arms and legs.   
▪ Exam - mild proximal and distal weakness of all extremities, trace arm and 
absent leg reflexes and mild distal sensory loss. 
 
▪ A 54 year old with a 12-24 hour history of rapidly progressive weakness and 
inability to ambulate.  This began while golfing the previous afternoon.   
▪ Exam reveals flaccid weakness of all four extremities and facial weakness. 
Areflexic throughout.  Within 3 hours of admission he is intubated for 
respiratory failure.   
 
Diagnostic Criteria for Guillain Barre 
Syndrome (GBS) 
Required 
 Progressive weakness in more than 1 limb 
 Areflexia or hyporeflexia 
Supportive 
 Progression in less than 4-6 weeks 
 Symmetric weakness 
   Sensory symptoms/signs 
 Autonomic dysfunction 
 Cranial nerve involvement, VII 
 Elevated CSF protein, cell count < 20 
 Demyelination by nerve conduction studies 
Features Casting Doubt in GBS 
 Marked asymmetry 
 Early bowel or bladder dysfunction 
 Sensory level 
 > 50 cells/mm3 in CSF, polys 
GBS - Etiology 
▪ Most common cause of acute generalized 
weakness - mean age 40 
▪ Mortality 5%  
▪ 85% have a full functional recovery 
▪ Usually preceded 1 to several weeks by 
systemic infection 
• Campylobacter, EBV, CMV, URI,  
• HIV seroconversion 
GBS - Treatment 
▪ Supportive Care - ICU, DVT prophylaxis 
▪ FVC’s - intubation  <15 - 20cc/kg 
▪ Autonomic instability 
▪ Plasma exchange 
• 200-250cc/kg total over 5 - 14 days 
▪ Intravenous Immunoglobulin 
• 2g/kg total at 400 mg/kg/day 
▪ Immediate dramatic improvement not the rule 
▪ Steroids not helpful 
Conclusions 
▪ Good H&P and neurologic exam 
▪ Look for patterns of weakness and sensory loss 
▪ Differential diagnosis 
▪ Routine vs. acute neuropathies 
▪ How EMG/NCS helps? 
▪ Primary and consider secondary blood work 
▪ Treatments - not only symptomatic 
 
